ClinicalTrials.gg
TerminatedNCT06779851SUMMIT-1Updated Apr 22, 2026

A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of BPT567 in Advanced Solid Tumors, sponsored by Bright Peak Therapeutics Inc. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Bright Peak Therapeutics Inc · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Solid Tumors
03

In context

Lead sponsor

This is the only study on the registry with Bright Peak Therapeutics Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥18 years at the time of signing form
  • per 1.1
  • - or cytologically-diagnosed, locally advanced unresectable or solid tumor. Progressed or recurred after previously having received approved standard of care agents that are approved and available in their local geography.
  • Performance status of 0 or 1
  • of at least 3 months
  • Adequate organ and marrow function
  • during study participation, as applicable

Exclusion criteria

Exclusion Criteria:

  • Has received systemic small molecule therapy or radiation therapy within 28 days prior to the first dose.
  • Treatment with biologic agents including or PD-L1 antibodies for less than 6 weeks or 5 half-lives, whichever is shorter, prior to first dose.
  • Received any agent less than 28 days or 5 half-lives, whichever is shorter, prior to the first dose.
  • Treatment with another IL-18 therapy.
  • Received systemic agents greater than the equivalent of prednisone 10mg daily within 14 days of the study, though inhaled, intranasal, topical or intra-articular are allowed.
  • Certain intercurrent disease.
  • Primary immune deficiency.
  • Active untreated brain or spine or .
  • Known seroposivitiy, although patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents are permitted.
  • Active hepatitis A or acute or chroming or C infection.
  • Received a within 30 days of enrollment or a COVD vaccine within 14 days.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Phase 1a Dose Escalation

    Study drug BPT567 at multiple dose levels to define MTD or MAD

    Drug: BPT567

  • Experimental
    Phase 1b Dose Expansion

    Study drug BPT567 at recommended dose for expansion (RDE) cohorts

    Drug: BPT567

Interventions

  • DrugBPT567

    Immunocytokine infusion

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT), Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)

    The MTD will be the highest tested dose of BPT567 at which protocol specified number of patients experience DLT or the MAD, highest administered dose in the absence of DLTs

    Time frame: Duration of first cycle (28 Days) for each cohort evaluated

  2. Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Rate of subjects reporting adverse events or serious adverse events including abnormalities in safety laboratory results

    Time frame: Through end of study (up to 2 years)

Secondary outcomes

  1. Pharmacokinetic parameter - Maximum Concentration (Cmax)

    Maximum concentration of BPT567

    Time frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)

  2. Pharmacokinetic parameter - Time to Maximumn Concentration (Tmax)

    Time to maximum concentration of BPT567

    Time frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)

  3. Pharmacokinetic parameter - Terminal Elimination Half-life (T1/2)

    Terminal elimination half-life of BPT567

    Time frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)

  4. Pharmacokinetic parameter - Area under the plasma concentration curve up to the last quantifiable time-point ((AUC)0-last))

    (AUC)0-last of BPT567

    Time frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)

  5. Pharmacokinetic parameter - Area area under the curve from 0 to infinite time (AUC0-inf)

    AUC0-inf of BPT567

    Time frame: Cycle 1 (Days 1,2, 4, 8, 15 & 22) Cycles 2& 3 (Days 1&15) Cycles 4 & beyond (Day1) End of Treatment (up to 2 years)

  6. Anti-drug Antibody (ADA) Response to BPT567

    Number of Participants With Anti-drug Antibody (ADA) Response to BPT567

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (up to 2 years)

  7. Objective response rate (ORR)

    Per RECIST V1.1

    Time frame: Through study completion up to 2 years

  8. Duration of response (DoR)

    Per RECIST V1.1

    Time frame: Through study completion up to 2 years

  9. Disease Control Rate (DCR)

    Per RECIST V1.1

    Time frame: Through study completion up to 2 years

  10. Progression Free Survival (PFS)

    Per RECIST V1.1

    Time frame: Through study completion up to 2 years

Other outcomes

  1. Evaluate changes in immune cell composition and tumor genome.

    Peripheral blood and/or tumour biopsy specimens may be analysed in an exploratory manner to assess changes in immune cell composition through immunophenotyping and cytokine level measurements.

    Time frame: Through study completion up to 2 years

07

Study locations

7 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85260, United States
  • Start Midwest
    Grand Rapids, Michigan 49546, United States
  • Hackensack Meridian John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Carolina BioOncology Institute
    Huntersville, North Carolina 28078, United States
  • Providence Cancer Institute
    Portland, Oregon 97213, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • South Texas Accelerated Research Therapeutics (START)
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2026, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 17, 2025
StartActual
Oct 15, 2024
Primary completionActual
Jan 21, 2026
CompletionActual
Mar 11, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06779851
Lead sponsor
Bright Peak Therapeutics Inc
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Oct 15, 2024
Primary completion
Jan 21, 2026
Completion
Mar 11, 2026
Last update
Apr 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion